Antimicrobial activity
ZERBAXA has been shown to be active against the following bacteria, both in vitro and in clinical infections.
- Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
|
|||
---|---|---|---|
|
|
||
|
|
||
|
|
||
|
|
Complicated urinary tract infections (cUTIs)
|
|||
---|---|---|---|
|
|
||
|
|
- Complicated intra-abdominal infections (cIAIs)
- combined with metronidazole
|
|||
---|---|---|---|
|
|
||
|
|
||
|
|
||
|
|||
|
|||
|
|||
|
|||
|
|||
|
Mechanisms of resistance
ZERBAXA is active in vitro in the presence of select key mechanisms of resistance
P. aeruginosa isolates with the most prevalent mechanisms of resistance (AmpC, loss of outermembrane porin, upregulation of efflux pumps) and some ESBLs